Latest News and Press Releases

PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference

PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range

PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme

PharmAla provides corporate update following AGM

PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.

PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans

PharmAla signs all-cash agreement to consult for Red Light Holland

PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines

PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License

PharmAla recieved a new OTCQB ticker, MDXXF.